DEFA14A: HOOKIPA Pharma and Poolbeg Pharma Announce Non-Binding Discussions for Potential Acquisition

HOOKIPA Pharma and Poolbeg Pharma are in preliminary talks for HOOKIPA to acquire Poolbeg in an all-share transaction, aiming to create a strong biopharmaceutical company.

Summary

• HOOKIPA Pharma Inc. and Poolbeg Pharma plc have entered non-binding discussions for a potential acquisition of Poolbeg by HOOKIPA.
• The proposed all-share transaction aims to create a combined biopharmaceutical company focused on developing innovative medicines for cancer and other serious diseases.
• The potential combination would be implemented via a scheme of arrangement under Part 26 of the Companies Act 2006.
• Poolbeg shareholders are expected to receive 0.03 HOOKIPA shares for each Poolbeg share held.
• Post-acquisition, Poolbeg shareholders are expected to own approximately 55% and HOOKIPA shareholders approximately 45% of the combined entity on a fully diluted basis, prior to a planned fundraise.
• HOOKIPA plans to undertake a private placement fundraise of up to approximately $30 million immediately following the completion of the potential combination.
• The fundraise is intended to provide capital for the combined business to achieve key value inflection points.
• The combined group would be debt-free with financial runway through year-end 2026, assuming receipt of future R&D grant proceeds from the Government of Austria.
• HOOKIPA shareholders will receive a contingent value right (CVR) related to certain HOOKIPA programs, including 55% of milestone payments from Gilead for HB-400 and HB-500, and 80% of proceeds from the HB-200 program.
• HOOKIPA intends to remain listed on the Nasdaq Capital Market, while Poolbeg is expected to become a private subsidiary and delist from AIM.
• The combined group is expected to have operations in the EU, UK, and USA, with a strong international leadership team.
• The announcement of a firm offer is subject to customary pre-conditions, including due diligence, finalization of terms, board approvals, and sufficient expressions of interest in the fundraise.
• There is no assurance that a firm offer will be made or that any transaction will be completed.

Sentiment

Score: 7

Explanation: The document presents a potentially positive development for both companies, with the aim of creating a stronger entity. However, the non-binding nature of the discussions and the various conditions and risks involved temper the overall sentiment.

Positives

• The potential combination creates a diversified clinical pipeline led by HB-700 and POLB 001.
• The combined group would have two partnered programs with Gilead Sciences, offering potential milestone payments and royalties.
• The fundraise is expected to provide sufficient capital for the enlarged business to realize meaningful value inflection points.
• HOOKIPA shareholders retain potential value from certain programs via a contingent value right (CVR).
• The combined group is expected to have a strong international leadership team.
• The combined company is expected to be debt free with cash runway through year-end 2026.

Negatives

• The discussions are currently non-binding, and there is no assurance that a firm offer will be made or that any transaction will be completed.
• The ownership percentages are subject to dilution based on the number of HOOKIPA shares issued in connection with the fundraise.
• The value of the CVR is subject to an adjustment mechanism based on HOOKIPA's net cash at completion of the potential combination.
• The completion of the fundraise is conditional upon completion of the potential combination (unless otherwise waived or amended).

Risks

• The potential combination is subject to customary pre-conditions, including due diligence, finalization of terms, and board approvals.
• The fundraise is contingent on the completion of the potential combination.
• The CVR value is subject to adjustment based on HOOKIPA's net cash position at closing.
• The combined company's financial runway through year-end 2026 is contingent on receiving future R&D grant proceeds from the Government of Austria.
• The success of the combined company depends on the successful development and commercialization of its pipeline programs.

Future Outlook

The combined company expects to have sufficient capital to realize meaningful value inflection points, with clinical data expected across multiple programs over the next 24 months and financial runway through year-end 2026.

Industry Context

The announcement reflects a trend of consolidation in the biopharmaceutical industry, where companies seek to diversify their pipelines and leverage synergies to accelerate drug development and commercialization.

Comparison to Industry Standards

• The proposed merger between HOOKIPA and Poolbeg is similar to other acquisitions in the biopharmaceutical industry where smaller companies with promising clinical assets are acquired by larger companies with more resources.
• The all-share structure of the deal is a common approach in mergers of this type, allowing shareholders of the acquired company to participate in the potential upside of the combined entity.
• The contingent value right (CVR) is a mechanism often used in acquisitions to bridge valuation gaps and align the interests of the acquirer and the target company's shareholders.
• The planned fundraise is intended to provide the combined company with sufficient capital to advance its clinical programs, which is a typical strategy in the biopharmaceutical industry.

Stakeholder Impact

• Shareholders of both HOOKIPA and Poolbeg will be impacted by the potential combination, with Poolbeg shareholders receiving HOOKIPA shares and potentially benefiting from the combined entity's future success.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the integration.
• The potential combination could lead to new opportunities for customers and partners of both companies.
• The combined company's creditors may be impacted by the transaction, depending on the terms of any debt financing involved.

Next Steps

• HOOKIPA and Poolbeg intend to engage with potential investors in the Fundraise.
• HOOKIPA is required to announce a firm intention to make an offer for Poolbeg, or announce that it does not intend to make an offer by January 30, 2025.
• The Potential Combination would be subject to the approval of both HOOKIPA and Poolbeg shareholders and other conditions.
• If a firm offer is made, HOOKIPA expects to file a proxy statement with the SEC.

Key Dates

Keywords

acquisition, HOOKIPA Pharma, Poolbeg Pharma, immunotherapy, biopharmaceutical, merger, fundraise, clinical pipeline, HB-700, POLB 001, Gilead, CVR